Suchergebnisse

Funding Information: We thank Markus Marks and other Fatih Yanik lab members for help with machine learning, Lise T. Jensen and Lars Fugger for sharing O-DTR mice, Takeshi Sakurai for sharing the orexin promoter used for generating HON specific constructs, Alan Ling and Adam Hurst at the Francis Crick Institute mechanical workshop for making recording arenas, staff at Vigene for technical assistance with viruses, Bruno Pichler and Dale Elgar for microscope design, Troy Margrie for sharing equipment, and all Burdakov lab members for useful comments and help. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement DRIVOME (grant agreement 701986 ). This work was funded by The Francis Crick Institute , which receives its core funding from Cancer Research UK ( FC001055 ), the UK Medical Research Council ( FC001055 ), and the Wellcome Trust ( FC001055 ). AA was supported by the Human Frontier Science Program , Inselspital University Hospital Bern , Swiss National Science Foundation , European Research Council , the University of Bern and the Bern University Hospital . ; Peer reviewed ; Publisher PDF

Tao Han,1,* Xiaodan Yang,1,* Ying Xu,2,* Zhendong Zheng,1,* Ying Yan,2 Ning Wang2 1Department of Oncology, 2Department of Radiotherapy, General Hospital of Shenyang Military Region, Shenyang, China *These authors contributed equally to this work Objective: To explore the therapeutic value of 3-D printing template-assisted 125I-seed implantation in the treatment of malignant liver tumors.Materials and methods: Fifteen liver cancer patients with 47 total lesions were treated with 3-D printing template-assisted radioactive seed implantation (group A), and 25 liver-tumor patients with 66 total lesions were treated with 125I-seed implantation without a template auxiliary (group B). Operation time, in-hospital time, operation complications, dose distribution, and response rate (number) were compared between the two groups. Results: Shorter operation times and better dose distribution were observed in group A than in group B, and the differences were statistically significant. The response rate after 2 months was 86.7% (13 of 15) in group A and 84% (21 of 25) in group B; differences between the two groups were not significant.Conclusion: Application of 3-D printing template-assisted radioactive seed implantation in the treatment of malignant liver tumors can help shorten operation time and optimize radiation-dose distribution, is worthy of further study, and has clinical significance. Keywords: brachytherapy, stereotactic techniques, iodine isotopes, liver, carcinoma

Zhenyu Ding,1,* Tong Jiang,2,* Ying Piao,1 Tao Han,1 Yaling Han,3 Xiaodong Xie1 1Department of Oncology, General Hospital of Shenyang Military Region, Shenyang City, Liaoning Province, 2Laboratory of Military Health in Cold Region, Center for Disease Control and Prevention of Shenyang Military Region, Shenyang City, Liaoning Province, 3Institute of Cardiovascular Disease, General Hospital of Shenyang Military Region, Shenyang City, Liaoning Province, People's Republic of China *These authors contributed equally to this work Abstract: Previous studies investigating the association between adenomatous polyposis coli (APC) gene promoter methylation and colorectal cancer (CRC) have yielded conflicting results. The aim of this study was to comprehensively evaluate the potential application of the detection of APC promoter methylation to the prevention and treatment of CRC. PubMed, Embase, and MEDLINE (results updated to October 2014) were searched for relevant studies. The effect size was defined as the weighted odds ratio (OR), which was calculated using either the fixed-effects or random-effects model. Prespecified subgroup and sensitivity analyses were conducted to evaluate potential heterogeneity among the included studies. Nineteen studies comprising 2,426 participants were selected for our meta-analysis. The pooled results of nine studies comprising a total of 740 subjects indicated that APC promoter methylation was significantly associated with CRC risk (pooled OR 5.53; 95% confidence interval [CI] 3.50–8.76; P<0.01). Eleven studies with a total of 1,219 patients evaluated the association between APC promoter methylation and the presence of CRC metastasis, and the pooled OR was 0.80 (95% CI 0.44–1.46; P=0.47). A meta-analysis conducted with four studies with a total of 467 patients found no significant correlation between APC promoter methylation and the presence of colorectal adenoma (pooled OR 1.85; 95% CI 0.67–5.10; P=0.23). No significant correlation between APC promoter methylation and patients' Dukes' stage, TNM stage, differentiation grade, age, or sex was identified. In conclusion, APC promoter methylation was found to be significantly associated with a higher risk of developing CRC. The findings indicate that APC promoter methylation may be a potential biomarker for the carcinogenesis of CRC. Keywords: APC promoter methylation, colorectal cancer, meta-analysis

Tao Han,1,* Jianjun Chen,1,* Yuting Luan,2,* Xiaoxia Chen,1,* Xiaodan Yang,1 Yue Zhang,1 Gao Li,2 Di Wang,3 Zhendong Zheng1 1Department of Oncology, Cancer Center of People's Liberation Army, General Hospital of Shenyang Military Region, Shenyang 110840, People's Republic of China; 2Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110840, People's Republic of China; 3Department of Pathology, General Hospital of Shenyang Military Region, Shenyang 110840, People's Republic of China *These authors contributed equally to this work Abstract: Embryonal rhabdomyosarcoma (ERMS) has a low prevalence, poor prognosis, and limited treatment efficacy. We report a case of an 18-year-old male whose disease relapsed in the abdominal cavity after a testicular ERMS curative resection. The patient received eight sequential cycles of rescue therapy using cisplatin and isocyclophosphamide in combination with a vascular targeted drug, Endostar. The therapeutic effect of the combination regimen has been evaluated for complete response. This is the first case to report using Endostar and chemotherapy in relapsed ERMS, and the curative effect results in complete response. Endostar, a new vascular targeted drug, combined with chemotherapy may play a synergistic role and provide a reference for the treatment of ERMS. Keywords: embryonal rhabdomyosarcoma, metastasis, complete response, endogenous angiogenesis inhibitor

Tao Han,1,* Zhaozhe Liu,1,* Hengyu Li,2,* Wanqing Xie,3,* Ranran Zhang,1 Li Zhu,2 Fang Guo,1 Yaling Han,4 Yuan Sheng,2 Xiaodong Xie11Department of Oncology, Cancer Center of People's Liberation Army, General Hospital of Shenyang Military Region, Shenyang, People's Republic of China; 2Department of Thyroid and Breast Surgery, Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China; 3Liaoning University of Traditional Chinese Medicine, Shenyang, People's Republic of China; 4Department of Cardiology, Institute of Cardiovascular Research of People's Liberation Army, General Hospital of Shenyang Military Region, Shenyang, People's Republic of China*These authors contributed equally to this workBackground: Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is prone to recurrence and metastasis with worse prognosis. Epirubicin-based chemotherapy is of great importance for patients with TNBC, but resistance to epirubicin severely limits the application of this drug and this has emerged as a major problem in the treatment of TNBC. The ubiquitin protein D (UBD) molecule has often been considered a tumor oncogene, and has been shown to promote the recurrence and metastasis of malignant tumor cells. Since the role of UBD in epirubicin resistance and its prognostic value in TNBC have not been reported, the study reported here was designed to identify the epirubicin-resistance molecule and clarify the related biomarker for TNBC prognosis.Methods: UBD plasmid was transfected into MDA-MB-231 cells, and the cells were exposed to epirubicin to observe the ability of UBD in epirubicin resistance. UBD expression was also detected in 78 breast cancer tissues by immunohistochemistry. Statistical methods were used to study the relationship between UBD expression and epirubicin resistance in TNBC treatment. Kaplan–Meier survival analysis was used to determine the correlation between UBD expression and TNBC patients' prognostic parameters.Results: UBD expression was found increased in breast cancer tissues. Forced UBD expression was found to have a relationship with TNBC epirubicin resistance in vitro. High expression of UBD was found in TNBC, compared with in non-TNBC, and this played a positive role in epirubicin resistance and indicated the poor prognosis of TNBC treatment.Conclusion: UBD may play an important role in epirubicin resistance in TNBC. UBD has the potential to be a novel biomarker in TNBC chemoresistance and may be a promising therapeutic target for TNBC patients.Keywords: prognosis, chemoresistance, biomarker

Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder characterized by fluctuating proximal limb muscle weakness, decreased deep tendon reflexes and various autonomic symptoms. LEMS is reportedly the most common neurological paraneoplastic syndrome. This is the case report of a patient with small-cell lung cancer (SCLC) who developed LEMS. A 68-year-old male patient presented with a 6-month history of progressive weakness of the proximal limbs and a 2-month history of xerostomia. The patient was admitted to the Department of Neurology of the People's Liberation Army General Hospital of Shenyang Military Region (Shenyang, China). The symptoms of the patient were not relieved with supportive therapy. Further laboratory tests, electrodiagnostic studies, chest computed tomography and immunohistochemical staining confirmed the diagnosis of LEMS in the presence of SCLC. Following administration of two cycles of rescue chemotherapy with a combination of etoposide and cisplatin, the symptoms of the patient were gradually relieved and, after six cycles of therapy, the primary malignancy completely regressed. In conclusion, a diagnosis of LEMS may lead to the timely detection of SCLC, significantly improving patient prognosis and survival.